Serous ovarian carcinoma (SOC) is an ovarian cancer with a high fatality rate. Therefore, a lot of researchers have tried to identify novel prognostic biomarkers which might improve the patient prognosis. The aims of the study were to detect the tissue protein expression of Beclin-1 in addition to HIF-1α in SOC patients, to evaluate the relationship between their expression, the clinicopathological parameters, patients' prognosis, and the relation to chemotherapy resistance in SOC. We evaluated the expression of Beclin-1 in addition to HIF-1α in 60 patients with SOC using immunohistochemistry, followed all patients for about 36 months, analyzed associations between both markers' expression, clinicopathological data, and patients' prognosis. Beclin-1 expression was related to low grade (p = 0.002), early SOC stage, absence of peritoneal spread (p = 0.006), and absence of lymph nodes, and distant metastases (p = 0.004 and < 0.001 respectively), while HIF-1α expression was associated with higher grade and stage (p = 0.007), and presence of nodal and distant metastases (p < 0.001 and = 0.012 respectively). High Beclin-1 expression and low HIF-1α expression were positively associated with good response to chemotherapy (p = 0.047 and p = 0.022 respectively), a lower recurrence rate after successful therapy (p = 0.006 and < 0.001 respectively), and increased three-year recurrence-free and overall survival rates (p < 0.001). In SOC patients; Beclin-1 is a good prognostic marker, while HIF-1α is a poor prognostic marker.
Ovarian malignancy is diagnosed in nearly a fourth of a million women internationally every year. Methylation of RASSF1A tumor suppressor gene prompts its inactivation in diseases. In this study, the RASSF1A promoter methylation was detected by methylated-specific PCR and investigated serum RASSF1A protein level through enzyme-linked immunosorbant assay in 160 Egyptian patients with ovarian cancer and 160 healthy controls. The present work proved that there was a higher frequency of RASSF1A methylation and a decrease in its serum level in patients with ovarian cancer compared to controls as well as in the high-grade tumor patients compared to low grade ones and also in advanced ovarian tumor stage compared to early stages. Our study exhibited that RASSF1A promoter hypermethylation and its protein levels may be a reliable and sensitive tool for diagnosing and monitoring of ovarian malignancy patients.
Background. Detection of novel predictive markers for early detection of lymph nodes metastases in cervical cancer is very important. Disturbed NR2F6 expression was found in many cancers playing different roles according to cancer type. LOXL2 was incriminated in cancer progression and unfavorable survival in many cancer types. Decreased DMBT1 expression was found in many cancers during their progression. Aim of the present work was to assess expression of NR2F6, LOXL2 and DMBT1 in cervical cancer tissues using immunohistochemistry then correlating their expression with grade and stage of the tumor, occurrence of lymph nodes and distant metastases in addition to evaluating their prognostic roles. Materials and methods. We assessed the expression of NR2F6, LOXL2 and DMBT1 in samples retrieved from sixty two cervical cancer patients in cancer tissues and corresponding adjacent normal tissues and we correlated markers expression with clinical data, pathological findings and patients' prognosis. Results. High expression of NR2F6, LOXL2 and low expression of DMBT1 was up-regulated in cervical cancer tissues more than in adjacent non-neoplastic cervical tissues and was associated with high grade (p = 0.005), lymphovascular space involvement, advanced FIGO stage, resistance to chemotherapy, tumor recurrence, and shorter survival rates (p < 0.001). Conclusions. Up regulation of NR2F6, LOXL2 and down regulation of DMBT1 were associated with unfavorable pathological parameters, bad clinical findings and dismal outcome of cervical cancer patients.
SOMMARIOContesto. La rilevazione di nuovi marcatori predittivi per la diagnosi precoce delle metastasi linfonodali nel cancro cervicale è molto importante. L'espressione distorta di NR2F6 è stata trovata in molti tumori che svolgono ruoli diversi a seconda del tipo di cancro. LOXL2 è stato incriminato nella progressione del cancro e nella sopravvivenza sfavorevole in molti tipi di cancro. La diminuzione dell'espressione di DMBT1 è stata trovata in molti tumori durante la loro progressione. Lo scopo del presente lavoro era valutare l'espressione di NR2F6, LOXL2 e DMBT1 nei tessuti del cancro cervicale mediante immunoistochimica, quindi correlando la loro espressione con il grado e lo stadio del tumore, la presenza di linfonodi e metastasi a distanza, oltre a valutare i loro ruoli prognostici. Materiali e metodi. Abbiamo valutato l'espressione di NR2F6, LOXL2 e DMBT1 in campioni prelevati da sessantadue pazienti con cancro cervicale nei tessuti tumorali e nei corrispondenti tessuti normali adiacenti e abbiamo correlato l'espressione dei marcatori con i dati clinici, i risultati patologici e la prognosi dei pazienti. Risultati. L'alta espressione di NR2F6, LOXL2 e la bassa espressione di DMBT1 erano sovraregolate nei tessuti del cancro cervicale più che nei tessuti cervicali adiacenti non neoplastici ed erano associate ad alto grado (p = 0,005), coinvolgimento dello spazio linfovascolare, stadio FIGO avanzato, resistenza a chemioterapia, recidiva del tumore e tassi di sopravvivenza pi...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.